Induction of antitumor immunity with dendritic cells transduced with adenovirus vector-encoding endogenous tumor-associated antigens

Journal of Immunology

Volumn 163, Issue 2, 1999, Pages 699-707

  Kaplan, Johanne M ^a   Yu, Queendy ^a   Piraino, Susan T ^a   Pennington, Sarah E ^a   Shankara, Srinivas ^a   Woodworth, Lisa A ^a   Roberts, Bruce L ^b  

^a GENZYME CORPORATION   (United States)

^b Genzyme Molecular Oncology   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TUMOR ANTIGEN;

ADENOVIRUS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER INHIBITION; CELL ACTIVITY; CONTROLLED STUDY; DENDRITIC CELL; FEMALE; FIBROBLAST; GENETIC TRANSDUCTION; HELPER CELL; IMMUNOTHERAPY; MELANOMA CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR IMMUNITY;

ADENOVIRIDAE; ANIMALS; ANTIGENS, NEOPLASM; BONE MARROW CELLS; CD4-POSITIVE T-LYMPHOCYTES; DENDRITIC CELLS; FEMALE; GENETIC VECTORS; HUMANS; IMMUNOTHERAPY, ACTIVE; IMMUNOTHERAPY, ADOPTIVE; MELANOMA, EXPERIMENTAL; MEMBRANE GLYCOPROTEINS; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; NEOPLASM PROTEINS; T-LYMPHOCYTES, CYTOTOXIC; TRANSFECTION;

EID: 0033565915     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Bakker, A. B. H., M. W. J. Schreurs, A. J. de Boer, Y. Kawakami, S. A. Rosenberg, G. J. Adema, and C. G. Figdor. 1994. Melanocyte lineage-specific antigen gp100 is recognized by melanoma-derived tumor-infiltrating lymphocytes. J. Exp. Med. 179:1005.
2. Kawakami, Y., S. Eliyahu, C. H. Delgado, P. F. Robbins, L. Rivoltini, S. L. Topalian, T. Miki, and S. A. Rosenberg. 1994. Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor. Proc. Natl. Acad. Sci. 91:3515.
3. Van Der Bruggen, P., C. Traversari, P. Chomez, C. Lurquin, E. De Plaen, B. Van Den Eynde, A. Knuth, and T. Boon. 1991. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 254:1643.
4. Brichard, V., A. Van Pel, T. Wolfel, C. Wolfel, E. De Plaen, B. Lethe, P. Coulie, and T. Boon. 1993. The tyrosinase gene codes for an antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas. J. Exp. Med. 178: 489.
5. Wang, R.-F., and S. A. Rosenberg. 1996. Human tumor antigens recognized by T lymphocytes: implications for cancer therapy. J. Leukocyte Biol. 60:296.
6. Steinman, R. M. 1991. The dendritic cell system and its role in immunogenicity. Annu. Rev. Immunol. 9:271.
7. Steinman, R. M., M. Witmer-Pack, and K. Inaba. 1993. Dendritic cells: antigen presentation, accessory function and clinical relevance. Adv. Exp. Med. Biol. 329:1.
8. Caux, C., Y. J. Liu, and J. Banchereau. 1995. Recent advances in the study of dendritic cells and follicular dendritic cells. Immunol. Today 16:2.
9. Mayordomo, J. I., T. Zorina, W. J. Storkus, L. Zitvogel, C. Celluzzi, L. D. Falo, C. J. Melief, S. T. Ildstad, W. Martin Kast, A. B. DeLeo, and M. T. Lotze. 1995. Bone marrow-derived dendritic cells pulsed with synthetic tumour peptides elicit protective and therapeutic antitumour immunity. Nat. Med. 1:1297.
10. Mayordomo, J. I., D. J. Loftus, H. Sakamoto, C. M. De Cesare, P. M. Appasamy, M. T. Lotze, W. J. Storkus, E. Appella, and A. B. DeLeo. 1996. Therapy of murine tumors with p53 wild-type and mutant sequence peptide-based vaccines. J. Exp. Med. 183:1357.
11. Mayordomo, J. I., T. Zorina, W. J. Storkus, L. Zitvogel, M. D. Garcia-Prats, A. B. DeLeo, and M. T. Lotze. 1997. Bone marrow-derived dendritic cells serve as potent adjuvants for peptide-based antitumor vaccines. Stem Cells 15:94.
12. Zitvogel, L., J. I. Mayordomo, T. Tjandrawan, A. B. DeLeo, M. R. Clarke, M. T. Lotze, and W. J. Storkus. 1996. Therapy of murine tumors with tumor peptide-pulsed dendritic cells: dependence on T cells, B7 costimulation and T helper cell 1-associated cytokines. J. Exp. Med. 183:87.
13. Hsu, F. J., C. Benike, F. Fagnoni, T. M. Liles, D. Czerwinski, B. Taidi, E. G. Engleman, and R. Levy. 1996. Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells. Nat. Med. 2:52.
14. Nestle, F. O., S. Alijagic, M. Gilliet, Y. Sun, S. Grabbe, R. Dummer, G. Burg, and D. Schadendorf. 1998. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat. Med. 4:328.
15. Arthur, J. F., L. H. Butterfield, M. D. Roth, L. A. Bui, S. M. Kiertscher, R. Lau, S. Dubinett, J. Glaspy, W. H. McBride, and J. S. Economou. 1997. A comparison of gene transfer methods in human dendritic cells. Cancer Gene Ther. 4:17.
16. Bronte, V., M. W. Carroll, T. J. Goletz, M. Wang, W. W. Overwijk, F. Marincola, S. A. Rosenberg, B. Moss, and N. P. Restifo. 1997. Antigen expression by dendritic cells correlates with the therapeutic effectiveness of a model recombinant poxvirus tumor vaccine. Proc. Natl. Acad. Sci. 94:3183.
17. Brossart, P., A. W. Goldrath, E. A. Butz, S. Martin, and M. J. Bevan. 1997. Virus-mediated delivery of antigenic epitopes into dendritic cells as a means to induce CTL. J. Immunol. 158:3270.
18. Gong, J., L. Chen, D. Chen, M. Kashiwaba, Y. Manome, T. Tanaka, and D. Kufe. 1997. Induction of antigen-specific antitumor immunity with adenovirus-transduced dendritic cells. Gene Ther. 4:1023.
19. Song, W., H.-L. Kong, H. Carpenter, H. Torii, R. Granstein, S. Rafii, M. A. S. Moore, and R. G. Crystal. 1997. Dendritic cells genetically modified with an adenovirus vector encoding the cDNA for a model antigen induce protective and therapeutic antitumor immunity. J. Exp. Med. 186:1247.
20. Wan, Y., J., Bramson, R. Carter, F. Graham, and J. Gauldie. 1997. Dendritic cells transduced with an adenoviral vector encoding a model tumor-associated antigen for tumor vaccination. Hum. Gene Ther. 8:1355.
21. Zhai, Y., J. C. Yang, P. Spiess, M. I. Nishimura, W. W. Overwijk, B. Roberts, N. P. Restifo, and S. A. Rosenberg. 1997. Cloning and characterization of the genes encoding the murine homologues of the human melanoma antigens MART1 and gp100. J. Immunother. 20:15.
22. Bloom, M. B., D. Perry-Lalley, P. F. Robbins, Y. Li, M. El-Gamil, S. A. Rosenberg, and J. C. Yang. 1997. Identification of tyrosinase-related protein 2 as a tumor rejection antigen for the B16 melanoma. J. Exp. Med. 185:453.
23. Hirschowitz, E. A., S. Leonard, W. Song, B. Ferns, P. L. Leopold, J. J. Lewis, W. B. Bowne, S. Wang, A. N. Houghton, and R. G. Crystal. 1998. Adenovirus-mediated expression of melanoma antigen gp75 as immunotherapy for metastatic melanoma. Gene Ther. 5:975.
24. Gooding, L. R. 1979. Specificities of killing by T lymphocytes generated against syngeneic SV40 transformants: studies employing recombinants within the H-2 complex. J. Immunol. 122:1002.
25. Armentano, D., J. Zabner, C. Sacks, C. C. Sookdeo, M. P. Smith, J. A. St. George, S. C. Wadsworth, A. E. Smith, and R. J. Gregory. 1997. Effect of the E4 region on the persistence of transgene expression from adenovirus vectors. J. Virol. 71:2408.
26. Zhai, Y., J. C. Yang, Y. Kawakami, P. Speiss, S. C. Wadsworth, L. M. Cardoza, L. A. Couture, A. E. Smith, and S. A. Rosenberg. 1996. Antigen-specific tumor vaccines: development and characterization of recombinant adenoviruses encoding MART1 or gp100 for cancer therapy. J. Immunol. 156:700.
27. Armentano, D., C. C. Sookdeo, K. M. Hehir, R. J. Gregory, J. A. St. George, G. A. Prince, S. C. Wadsworth, and A. E. Smith. 1995. Characterization of an adenovirus gene transfer vector containing an E4 deletion. Hum. Gene Ther. 6:1343.
28. Rich, D. P., L. A. Couture, L. M. Cardoza, V. M. Giuggio, D. Armentano, P. C. Espino, K. Hehir, M. J. Welsh, A. E. Smith, and R. J. Gregory. 1993. Development and analysis of recombinant adenoviruses for gene therapy of cystic fibrosis. Hum Gene Ther. 4:461.
29. Inaba, K., M. Inaba, N. Romani, H. Aya, M. Deguchi, S. Ikehara, and R. M. Steinman. 1992. Generation of large numbers of dendritic cells from mouse bone marrow cultures supplemented with granulocyte/macrophage colony-stimulating factor. J. Exp. Med. 176:1693.
30. Coulie, P., M. Somville, F. Lehmannm P. Hainaut, F. Brassuer, R. Devos, and T. Boon. 1992. Precursor frequency analysis of human cytolytic T lymphocytes directed against autologous melanoma cells. Int. J. Cancer 50:289.
31. Taguchi, T., J. R. McGhee, R. L. Coffman, K. W. Beagley, J. H. Eldridge, K. Takatsu, and H. Kiyono. 1990. Detection of individual mouse splenic T cells producing IFN-γ and IL-5 using the enzyme-linked itnmunospot (ELISPOT) assay. J. Immunol. Methods 128:65.
32. Overwijk, W. W., A. Tsung, K. R. Irvine, M. R. Parkhurst, T. J. Goletz, K. Tsung, M. W. Carroll, C. L. Liu, B. Moss, S. A. Rosenberg, and N. P. Restifo. 1998. gp100/pmel 17 is a murine tumor rejection antigen: induction of self-reactive, tumoricidal T cells using high-affinity, altered peptide ligand. J. Exp. Med. 188: 277.
33. Crowley, M., K. Inaba, M. Witmer-Pack, and R. M. Steinman. 1989. The cell surface of mouse dendritic cells: FACS analyses of dendritic cells from different tissues including thymus. Cell. Immunol. 118:108.
34. Kaplan, J. M., D. Armentano, T. E. Sparer, S. G. Wynn, P. A. Peterson, S. C. Wadsworth, K. K. Couture, S. E. Pennington, J. A. St. George, L. R. Gooding, and A. E. Smith. 1997. Characterization of factors involved in modulating persistence of transgene expression from recombinant adenovirus in the mouse lung. Hum. Gene Ther. 8:45.
35. Shimizu, K., R. C. Fields, M. Giedlin, and J. J. Mule. 1999. Systemic administration of interleukin 2 enhances the therapeutic efficacy of dendritic cell-based tumor vaccines. Proc. Natl. Acad. Sci. USA 96:2268.
36. Romani, N., S. Gruner, D. Brang, E. Kampgen, A. Lenz, B. Trockenbacher, G. Konwalinka, P. O. Fritsch, R. M. Steinman, and G. Schuler. 1994 Proliferating dendritic cell progenitors in human blood. J. Exp. Med. 180:83.
37. Sallusto, F., and A. Lanzavecchia. 1994. Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and down-regulated by tumor necrosis factor α. J. Exp. Med. 179:1109.